Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P46976

UPID:
GLYG_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P46976; D3DNH0; D3DNH1; D3DNH2; Q6FHZ1; Q9UNV0

BACKGROUND:
The enzyme Glycogenin-1 is essential for initiating glycogen synthesis. By attaching glucose units to itself, it creates a primer for glycogen synthase, facilitating the conversion of glucose to glycogen. This function is vital for energy storage in cells, particularly in muscles.

THERAPEUTIC SIGNIFICANCE:
Mutations in Glycogenin-1 are linked to metabolic diseases such as Glycogen storage disease 15 and Polyglucosan body myopathy 2, leading to muscle dysfunction and abnormal glycogen storage. Targeting Glycogenin-1's pathway offers a promising avenue for developing treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.